Longitudinal observational studies to study the efficacy-effectiveness gap in drug therapy: Application to mild and moderate dementia

Nursing Clinics of North America

Volumn 41, Issue 1, 2006, Pages 105-117

  MacDonald, Karen M ^a   Vancayzeele, Stefaan ^b   Deblander, Anne ^b   Abraham, Ivo L ^a,c,d,e,f  

^a Matrix45   (United States)

^b Novartis Pharma Belgium   (Belgium)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e NEW YORK UNIVERSITY   (United States)

^f UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 32944477387     PISSN: 00296465     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cnur.2005.10.002     Document Type: Review

References (28)

1. ICH harmonised tripartite guideline. E2A: Clinical safety data management: definitions and standards for expedited reporting. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceutical for Human Use. Brussels, Belgium; October 27, 1994.
2. J.M. Last A dictionary of epidemiology 2nd edition 1988 Oxford University Press Oxford (UK)
3. Guidance for industry: premarketing risk assessment. US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research. Rockville, (MD); 2005.
4. Guidance for industry: good pharmacovigilance practices and pharmacoepidemiologic assessment. Rockville (MD): US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research. 2005.
5. A.M. Hake, and M.R. Farlow On the horizon: pathways for drug development in Alzheimer's disease Clin Geriatr Med 20 1 2004 141 152
6. H.S. Ruchlin, E.J. Dasbach, and J.F. Heyse New directions in pharmacoeconomic research: the next step Drug Inf J 36 2002 909 917
7. K. Benson, and A. Hartz A comparison of observational studies and randomized, controlled trials N Engl J Med 342 2000 1878 1886
8. J. Concato, N. Shah, and R. Horwitz Randomized, controlled trials, observational studies and the hierarchy of research designs N Engl J Med 342 2000 1887 1892
9. J.M. Eisenberg Health services research in a market-oriented health care system Health Aff 17 1998 98 108
10. Clinical practice guideline No. 1: acute pain management: operative or medical procedures and trauma; 1993. Rockville (MD): US Department of Health and Human Services. Agency for Health Care Policy and Research, Publication # 92-0023.
11. D.C. Hadorn, D. Baker, and J.S. Hodges Rating the quality if evidence for clinical practice guidelines J Clin Epidemiol 49 7 1996 749 754
12. nd edition 1996 Williams & Wilkins Baltimore (MD)
13. S. Timmermans, and A. Mauck The Promises and pitfalls of evidence-based medicine Health Aff 24 2005 18 28
14. L.S. Schneider, R. Anand, and M.R. Farlow Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease Int J Geriatr Psychopharmacol 1 1998 S26 S34
15. J. Cummings, R. Anand, and B. Koumaras Rivastigmine provides behavioral benefits to Alzheimer's disease patients residing in a nursing home: findings from a 56-week trial Neurology 54 Suppl 3 2000 A468 A469
16. R. Bullock, R. Moulias, and K.C. Steinwachs Effects of rivastigmine on behavioural symptoms in nursing home patients with Alzheimer's disease Int Psychogeriatr 13 Suppl 2 2001 242 Abstract P-248
17. B. Etemad Behavioral and cognitive benefits of rivastigmine in nursing home patients with Alzheimer's disease and related dementias: a 26-week follow-up Int Psychogeriatr 13 Suppl 2 2001 241 Abstract P-246
18. M.R. Farlow, A. Hake, and J. Messina The response of patients with Alzheimer's disease to rivastigmine treatment is predicted by the rate of disease progression Arch Neurol 58 2001 417 422
19. M. Rösler, W. Retz, and P. Retz-Junginger Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease Behav Neurol 11 1998 211 216
20. Santaguida PS, Raina P, Booker L, et al. Pharmacological treatment of dementia. Evidence report/technology assessment No. 97; 2004 (prepared by McMaster University Evidence-Based Practice Center under Contract No. 290-02-0020). Rockville (MD): Agency for Healthcare Research and Quality, Publication #04-E018-2.
21. M. Folstein, S.E. Folstein, and P.R. McHugh "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 12 3 1975 189 198
22. B. Reisberg, S.H. Ferris, and M.J. de Leon The Global Deterioration Scale for assessment of primary degenerative dementia Am J Psychiatry 139 9 1982 1136 1139
23. S. Katz, A.B. Ford, and R.W. Moskowitz Studies of illness in the aged: the index of ADL: a standardized measure of biological and psychosocial function JAMA 185 1963 914 919
24. M.P. Lawton, and E.M. Brody Assessment of older people: self-maintaining and instrumental activities of daily living Gerontologist 9 3 1969 179 186
25. J.L. Cummings, M. Mega, and K. Gray The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia Neurology 44 12 1994 2308 2314
26. S.H. Zarit, K.E. Reever, and J. Bach-Peterson Relatives of the impaired elderly: correlates of feelings of burden Gerontologist 20 1980 649 655
27. D. Goldberg General Health Questionnaire (GHQ-12) 1992 NFER-Nelson Windsor (UK)
28. D.J. Pevalin Multiple applications of the GHQ-12 in a general population sample: an investigation of long-term retest effects Soc Psychiatry Psychiatr Epidemio 35 2000 508 512